Stock Opinions by Paul MacDonald - Stockchase Experts
WATCH LIST
165
Paul MacDonald

On Stockchase since : Jun 2016

Chief Investment Officer & Portfolio Manager at Harvest Portfolios Group

Reveal Expert Performance

Paul MacDonald hasn’t left any messages.


Paul MacDonald Latest Top Picks...

Stock Opinions by Paul MacDonald - Stockchase Experts

Signal Opinion Expert Chart
COMMENT
Stock market buoyancy today. Market of two tales. Any correction in growth names, like tech and consumer discretionary, tends to get bought. Good numbers are coming in. Defensives like healthcare and utilities are a different story.
0 0 0 0 0
0 comments
Stock market buoyancy today. Market of two tales. Any correction in growth names, like tech and consumer discretionary, tends to get bought. Good numbers are coming in. Defensives like healthcare and utilities are a different story.
Unknown
0 0 0 0 0
0 comments
Paul MacDonald

Chief Inve, Harvest Portfolios G...

Price Price
$0.000
Owned Owned
Unknown

Sign up or Log in to enjoy full view of charts.

COMMENT
Golden opportunity to get into healthcare? Positives are there such as aging population, developing markets, new technologies set the stage for long-term positive dynamics. In the shorter term, polarized extreme views have come out, but there's no substance to them. The correction is just noise, and it's a well-timed entry point in the sector. Bernie Sanders' "medicare for all" inspired a downturn. Technical healthcare names have held up.
0 0 0 0 0
0 comments
Golden opportunity to get into healthcare? Positives are there such as aging population, developing markets, new technologies set the stage for long-term positive dynamics. In the shorter term, polarized extreme views have come out, but there's no substance to them. The correction is just noise, and it's a well-timed entry point in the sector. Bernie Sanders' "medicare for all" inspired a downturn. Technical healthcare names have held up.
Unknown
0 0 0 0 0
0 comments
Paul MacDonald

Chief Inve, Harvest Portfolios G...

Price Price
$0.000
Owned Owned
Unknown

Sign up or Log in to enjoy full view of charts.

BUY
Diversity is key. Large biotech has been beat up. Speculation that Novartis is a competitor, but it's at early stages for them. REGN does have a drug for a niche market. Correction is in part because of Novartis speculation plus medicare reimbursement. Current multiple around 13x, you can buy it, but buy it in a basket.
Pharma & Healthcare
0 0 0 0 0
0 comments
Diversity is key. Large biotech has been beat up. Speculation that Novartis is a competitor, but it's at early stages for them. REGN does have a drug for a niche market. Correction is in part because of Novartis speculation plus medicare reimbursement. Current multiple around 13x, you can buy it, but buy it in a basket.
Pharma & Healthcare
0 0 0 0 0
0 comments
Paul MacDonald

Chief Inve, Harvest Portfolios G...

Price Price
$336.890
Owned Owned
Unknown

Sign up or Log in to enjoy full view of charts.

COMMENT
Medical device ETF? Likes medical devices, and they've significantly outperformed the other sub-sectors. Tend to be less susceptible to the political noise. Great earnings growth. But if we see an improvement to some of the other sub-sectors, we could see them underperform the others. So have a diversified portfolio in that space.
0 0 0 0 0
0 comments
Medical device ETF? Likes medical devices, and they've significantly outperformed the other sub-sectors. Tend to be less susceptible to the political noise. Great earnings growth. But if we see an improvement to some of the other sub-sectors, we could see them underperform the others. So have a diversified portfolio in that space.
Unknown
0 0 0 0 0
0 comments
Paul MacDonald

Chief Inve, Harvest Portfolios G...

Price Price
$0.000
Owned Owned
Unknown

Sign up or Log in to enjoy full view of charts.

HOLD
Pfizer Inc(PFE-N) 

May 3, 2019

A long-term play. Low EPS growth of about 3.5-4%. Very large company. Don't have a lot of drugs that have exposure over 10%, except Prevnar. Not his favourite growth position. Diversity of assets. Need to do some M&A. Stable dividend. Only paying 15x. You can hold on to this.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A long-term play. Low EPS growth of about 3.5-4%. Very large company. Don't have a lot of drugs that have exposure over 10%, except Prevnar. Not his favourite growth position. Diversity of assets. Need to do some M&A. Stable dividend. Only paying 15x. You can hold on to this.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul MacDonald

Chief Inve, Harvest Portfolios G...

Price Price
$41.390
Owned Owned
Unknown

Sign up or Log in to enjoy full view of charts.

BUY
AbbVie Inc.(ABBV-N) 

May 3, 2019

Good entry point. Main drug Humira is $20B per year, and yes, its patent will expire in 2021. But they've been reinvesting that cash cow in other drugs. Paying 9x earnings, so it's cheap. Could consolidate around $100. Great dividend, balance sheet. Own it in a basket.

0 0 0 0 0
0 comments

Good entry point. Main drug Humira is $20B per year, and yes, its patent will expire in 2021. But they've been reinvesting that cash cow in other drugs. Paying 9x earnings, so it's cheap. Could consolidate around $100. Great dividend, balance sheet. Own it in a basket.

0
0 0 0 0 0
0 comments
Paul MacDonald

Chief Inve, Harvest Portfolios G...

Price Price
$78.710
Owned Owned
Unknown

Sign up or Log in to enjoy full view of charts.

COMMENT
Demonstrates how binary risk can happen in individual securities. Big driver recently has been failure in an Alzheimer's study. Had to shut the study down, which caught the market by surprise. Likes it, though risk in this stock is high, with a relatively high rate of return. For all large cap biotech, make sure you have at least a couple of positions.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Demonstrates how binary risk can happen in individual securities. Big driver recently has been failure in an Alzheimer's study. Had to shut the study down, which caught the market by surprise. Likes it, though risk in this stock is high, with a relatively high rate of return. For all large cap biotech, make sure you have at least a couple of positions.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul MacDonald

Chief Inve, Harvest Portfolios G...

Price Price
$231.180
Owned Owned
Unknown

Sign up or Log in to enjoy full view of charts.

WATCH
Likes it. One of better growth profiles for large cap pharma. Exceptional job building out the pipeline in oncology and diabetes. Cardiac drug seems like becoming the standard of care. Some hiccups, but the market gave them a pass. 14-15% EPS growth. 17x next year's earnings. Make sure the launches are on track next quarter.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Likes it. One of better growth profiles for large cap pharma. Exceptional job building out the pipeline in oncology and diabetes. Cardiac drug seems like becoming the standard of care. Some hiccups, but the market gave them a pass. 14-15% EPS growth. 17x next year's earnings. Make sure the launches are on track next quarter.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul MacDonald

Chief Inve, Harvest Portfolios G...

Price Price
$116.970
Owned Owned
Yes

Sign up or Log in to enjoy full view of charts.

PAST TOP PICK
Celgene Corp(CELG-Q) 

May 3, 2019

(A Top Pick Mar 21/18, Up 10%) Sold it because it's getting taken out by Bristol Myers.
Consumer Products
0 0 0 0 0
0 comments
(A Top Pick Mar 21/18, Up 10%) Sold it because it's getting taken out by Bristol Myers.
Consumer Products
0 0 0 0 0
0 comments
Paul MacDonald

Chief Inve, Harvest Portfolios G...

Price Price
$96.780
Owned Owned
No

Sign up or Log in to enjoy full view of charts.

PAST TOP PICK
(A Top Pick Mar 21/18, Up 51%) Really likes it. A top pick for several years. Immunotherapy drug for cancer is leading the pack. Leader in the space.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Mar 21/18, Up 51%) Really likes it. A top pick for several years. Immunotherapy drug for cancer is leading the pack. Leader in the space.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul MacDonald

Chief Inve, Harvest Portfolios G...

Price Price
$80.000
Owned Owned
Yes

Sign up or Log in to enjoy full view of charts.

PAST TOP PICK
Stryker Corp.(SYK-N) 

May 3, 2019

(A Top Pick Mar 21/18, Up 17%) Fantastic company in diverse medical devices. Leader in hip and knee replacements. Latest quarter was fantastic.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Mar 21/18, Up 17%) Fantastic company in diverse medical devices. Leader in hip and knee replacements. Latest quarter was fantastic.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul MacDonald

Chief Inve, Harvest Portfolios G...

Price Price
$190.710
Owned Owned
Yes

Sign up or Log in to enjoy full view of charts.

HOLD
Diversity is key in the space. Has a lot of small caps, so will increase volatility. If you can buy a basket of large cap biotechs, that would be the way to go right now. In this space, buy the basket is the most prudent way to go. Individual names bring high risk.
E.T.F.'s
0 0 0 0 0
0 comments
Diversity is key in the space. Has a lot of small caps, so will increase volatility. If you can buy a basket of large cap biotechs, that would be the way to go right now. In this space, buy the basket is the most prudent way to go. Individual names bring high risk.
E.T.F.'s
0 0 0 0 0
0 comments
Paul MacDonald

Chief Inve, Harvest Portfolios G...

Price Price
$107.910
Owned Owned
Unknown

Sign up or Log in to enjoy full view of charts.

HOLD
Large cap, diversified. Long life assets. They need to find growth and acquisitions. Healthy distribution. Analysts question the dividend. Low growth profile. A strong hold, but be cognizant that they need to buy companies to fill out the pipeline and keep up the dividend growth.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Large cap, diversified. Long life assets. They need to find growth and acquisitions. Healthy distribution. Analysts question the dividend. Low growth profile. A strong hold, but be cognizant that they need to buy companies to fill out the pipeline and keep up the dividend growth.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul MacDonald

Chief Inve, Harvest Portfolios G...

Price Price
$40.750
Owned Owned
Yes

Sign up or Log in to enjoy full view of charts.

COMMENT
There is hope for it. Good news is the generic price declines have subsided, but "less declines" is not where he wants to be right now. Challenged in the next 12-18 months. Could go to low 20s, but structural headwinds for the business.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
There is hope for it. Good news is the generic price declines have subsided, but "less declines" is not where he wants to be right now. Challenged in the next 12-18 months. Could go to low 20s, but structural headwinds for the business.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul MacDonald

Chief Inve, Harvest Portfolios G...

Price Price
$15.180
Owned Owned
No

Sign up or Log in to enjoy full view of charts.

HOLD
Medtronic Inc(MDT-N) 

May 3, 2019

Don't sell it just to go into a Merck. Add to your diversity instead by buying a basket. Likes Medtronic. Diversified. Into robotic surgery. 8% EPS growth. Relatively inexpensive. Very large, so you don't get the same growth as smaller companies.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Don't sell it just to go into a Merck. Add to your diversity instead by buying a basket. Likes Medtronic. Diversified. Into robotic surgery. 8% EPS growth. Relatively inexpensive. Very large, so you don't get the same growth as smaller companies.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul MacDonald

Chief Inve, Harvest Portfolios G...

Price Price
$89.580
Owned Owned
Unknown

Sign up or Log in to enjoy full view of charts.

Showing 1 to 15 of 165 entries
Successfully Saved Company
Successfully Saved Company